Financial Performance - The company reported a net loss of €24.8 million for the first half of 2024, compared to a net income of €1.7 million for the same period in 2023[10]. - Revenue and other income decreased by €27.9 million to €12.3 million for the six months ended June 30, 2024, down from €40.2 million in the same period of 2023[12]. - Revenue from collaboration and licensing agreements was €8.3 million, a significant decrease from €35.3 million in the first half of 2023[13]. - The company expects to incur additional losses until it can generate significant revenues from its drug candidates in development[7]. - Basic loss per share for the six months ended June 30, 2024, was €(0.31), compared to a basic income per share of €0.02 for the same period in 2023[141]. Revenue Breakdown - Revenue from collaboration and licensing agreements decreased by €27.1 million, to €8.3 million for the six months ended June 30, 2024, compared to €35.3 million for the same period in 2023, representing a decline of approximately 76.7%[14]. - Revenue related to monalizumab decreased by €6.5 million, to €3.0 million for the six months ended June 30, 2024, compared to €9.5 million for the same period in 2023, a decrease of about 68.4%[17]. - Revenue from the Sanofi licensing agreement (2016) increased by €2.0 million, reaching €4.0 million for the six months ended June 30, 2024, compared to €2.0 million for the same period in 2023, marking a 100% increase[18]. - Revenues under the Takeda licensing agreement were nil for the first half of 2024, compared to €4.6 million for the first half of 2023, indicating a complete recognition of the initial payment in the previous year[23]. Research and Development Expenses - Operating expenses totaled €38.7 million, a decrease from €40.6 million in the first half of 2023, with 75.2% attributed to research and development[10]. - Research and development expenses were €29.1 million, down from €31.5 million in the first half of 2023, reflecting a 7.6% decrease[10]. - Personnel and other expenses allocated to R&D decreased by €2.2 million, or 15.4%, to €12.0 million for the six months ended June 30, 2024, compared to €14.2 million for the same period in 2023[36]. - Direct R&D expenses decreased by €0.2 million, or 1.1%, to €17.1 million for the six months ended June 30, 2024, primarily due to a €2.5 million increase in preclinical program expenses offset by a €2.7 million decrease in clinical program expenses[33]. Cash and Financial Position - Cash, cash equivalents, and financial assets amounted to €102.1 million as of June 30, 2024, slightly down from €102.3 million at the end of 2023[10]. - Financial liabilities were €35.5 million, including €26.6 million of non-current liabilities, compared to €39.9 million at the end of 2023[10]. - Total current assets decreased to €111.6 million as of June 30, 2024, down from €148.0 million at the end of 2023[57]. - Cash and cash equivalents amounted to €70.0 million as of June 30, 2024, a decrease of €0.6 million compared to December 31, 2023[46]. Employee and Operational Metrics - The company had 168 full-time equivalent employees as of June 30, 2024, down from 180 in the previous year[8]. - The company reported a total of 1,403,500 performance employees for the year 2023, with 66,250 being new members[105]. - The company plans to add 25,000 new members in 2024[105]. Deferred Revenue and Liabilities - Deferred revenue amounted to €6.9 million as of June 30, 2024, including €4.1 million booked as 'Deferred revenue – non-current portion'[45]. - The deferred revenue related to monalizumab as of June 30, 2024, is €2.0 million, classified entirely as "Deferred revenue—Current portion"[18]. - The total change in collaboration liabilities related to the monalizumab agreement decreased from €63,211 thousand as of December 31, 2022, to €56,058 thousand as of June 30, 2023[114]. Legal and Compliance - The Company has no acknowledged litigation as of June 30, 2024, indicating no significant legal risks at this time[132]. - The interim condensed consolidated financial statements were prepared in accordance with IAS 34 and IFRS standards[70].

Financial Data and Key Metrics Changes - The company reported a strong cash position with approximately EUR 115 million as of the end of March 2024, providing operational runway until the end of 2025 [63] Business Line Data and Key Metrics Changes - Lacutamab is being developed for cutaneous T cell lymphoma, with a focus on Sezary syndrome and mycosis fungoides, where KIR3DL2 is expressed in over 90% and approximately 50% of patients respectively [8] - The ANKET platform is advancing with IPH6501 entering Phase 1 trials, targeting CD20 in B-cell non-Hodgkin's lymphoma [9][51] - The ADC program IPH45 targeting Nectin-4 has shown strong anti-tumor efficacy in preclinical models, with plans to file an IND this year [28][56] Market Data and Key Metrics Changes - The company is pursuing a fast-to-market strategy for lacutamab in Sezary syndrome, having received U.S. fast track designation and EU PRIME designation [19] - The upcoming ASCO conference is expected to be significant for the company, with presentations on lacutamab and IPH6501 [32][50] Company Strategy and Development Direction - The company aims to develop innovative drug candidates that transform cancer care, focusing on a robust pipeline of differentiated antibody and antibody-derived drug candidates [46] - Partnerships with AstraZeneca and Sanofi are crucial for advancing the development of their proprietary products and expanding their pipeline [6][47] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data presentations at ASCO, which will inform regulatory discussions and potential market strategies [32][84] - The company is committed to addressing unmet medical needs in oncology, particularly in the crowded PTCL space, while leveraging its strong safety profile [77][90] Other Important Information - The company is actively exploring the potential of the ANKET platform beyond oncology, considering applications in autoimmune diseases [67] - The collaboration with Sanofi is prioritized within their oncology pipeline, with ongoing development of two ANKET molecules [72] Q&A Session Summary Question: What is the intent regarding biomarker thresholds in the TELLOMAK study? - The company is prospectively screening patients for KIR3DL2 expression levels and has created cohorts based on these levels to define potential biomarker thresholds [37] Question: What is the regulatory path forward for lacutamab after ASCO? - The aim is to ensure lacutamab reaches patients quickly, with plans to file with the FDA without additional registrational studies [41][42] Question: What updates can be expected from the collaboration with Sanofi? - The collaboration is active, with two ANKET molecules in development, and updates are anticipated this year [72] Question: Can you elaborate on the fast-to-market strategy for lacutamab? - The strategy includes the possibility of accelerated approval based on the ongoing registrational trial and the need for a 12-month durability of response [90] Question: What are the expectations for the PTCL data readout next year? - The PTCL space is crowded but presents unmet medical needs, and lacutamab's safety profile is a significant advantage [77]

Innate Pharma S.A. Sponsored ADR (IPHA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Indiv ...

Funding and Financial Position - The company may need to raise additional funding to complete the development and commercialization of its product candidates, which could delay or terminate its efforts if not obtained on acceptable terms[35]. - As of December 31, 2023, the company had cash, cash equivalents, short-term investments, and non-current financial assets totaling €102.3 million, which is expected to fund operations for the next two years[163]. - The company incurred significant operational losses related to its research and development activities, indicating a need for additional funding to complete product development and obtain regulatory approvals[163][166]. - The company may need to significantly curtail or discontinue research or development programs if it cannot obtain timely funding[166]. - The company may face restrictions on its operating and financial flexibility due to the terms of its loan agreements with Société Générale and BNP Paribas[167]. - The company has accumulated tax loss carryforwards of €483.6 million as of December 31, 2023, with limitations on their use under applicable French law[182]. - The company benefits from the Research Tax Credit, which amounted to €9.7 million, €7.9 million, and €10.3 million for the years ended December 31, 2023, 2022, and 2021, respectively[177]. - The company has obtained €28.7 million in non-dilutive financing through two State Guaranteed Loans, with an effective interest rate of 0.5% for repayment within one year[169]. Product Development and Clinical Trials - The company is developing several product candidates, including monalizumab, lacutamab, IPH5201, and IPH5301, which are currently in various stages of clinical trials[52]. - Monalizumab is being investigated in multiple Phase 1, 2, and 3 clinical studies under a co-development agreement with AstraZeneca[52]. - The company intends to continue developing its product candidates, but delays in preclinical or clinical development could adversely impact timelines[54]. - The company is seeking to develop a broad pipeline of product candidates, including those based on its innovative ANKET technology, but may face challenges in identifying viable candidates[56]. - The company has fast track designation in the U.S. and PRIME designation in the EU for lacutamab, aimed at expediting development for serious conditions[120]. - The FDA approved the initiation of a first-in-human study for the tetra-specific proprietary antibody IPH6501 in July 2023[57]. - The company has experienced clinical holds in the TELLOMAK study, impacting patient enrollment and treatment timelines[62]. - Patient enrollment for clinical studies is challenging, particularly for rare diseases like cutaneous T cell lymphoma (CTCL), which limits the potential patient population[64]. - Clinical studies are subject to delays and uncertainties, which may increase costs and hinder the ability to generate revenue[62]. - The company faces significant risks in product candidate development due to the innovative technology and the need for substantial resources[60]. Regulatory and Compliance Risks - The company faces significant risks related to the development of its product candidates, including the uncertainty of clinical trial outcomes and regulatory approvals[37]. - The company has never submitted a product candidate for marketing approval in the United States or the European Union[73]. - Regulatory approval processes are complex and can lead to delays or additional costs, impacting the commercialization of product candidates[70]. - The regulatory landscape is constantly evolving, which may result in unexpected changes that affect product development timelines and costs[78]. - Non-compliance with regulatory requirements could lead to substantial penalties, including withdrawal of products from the market[84]. - The company must navigate complex regulatory environments to obtain marketing approvals, which may differ significantly from those in the U.S. and Europe[81]. - Continuous regulatory review may lead to restrictions or withdrawal of marketing authorizations for approved product candidates[115]. - Regulatory authorities may impose costly post-marketing studies or clinical trials, which could affect the company's financial condition and operations[111]. - The company is subject to extensive healthcare laws and regulations, which could expose it to significant penalties and reputational harm if non-compliance occurs[125]. Market and Competitive Environment - Revenues from collaboration and license agreements are expected to contribute a significant portion of the company's revenue for the foreseeable future[35]. - The company competes with larger pharmaceutical companies that have more resources and experience in drug development and regulatory approvals[68]. - Market acceptance of product candidates is uncertain and depends on factors such as clinical efficacy, safety, and reimbursement policies from third-party payors[106]. - The company returned commercial rights of Lumoxiti to AstraZeneca due to lower-than-expected sales and challenges related to patient access and the COVID-19 pandemic[108]. - Future growth is contingent on the ability to penetrate multiple markets, which introduces additional regulatory and operational risks[113]. Operational and Personnel Challenges - The company relies on third-party manufacturers for all product candidates, which introduces risks related to quality, delivery times, and compliance with regulations[131]. - The company is dependent on third-party manufacturers and clinical research organizations (CROs) to conduct clinical studies, which poses risks related to compliance and data reliability[145]. - The company may face challenges in recruiting and retaining qualified personnel, particularly in key positions, which could impact its operations and growth prospects[217]. - As of December 31, 2023, Innate had 179 employees, indicating a need for additional personnel to support its development plans[212]. - The company relies on independent organizations and consultants for certain services, and any failure to manage these relationships could delay clinical trials and regulatory approvals[213]. Financial Performance and Losses - Innate Pharma reported a net loss of €(7.6) million for the year ended December 31, 2023, compared to a net loss of €(58.1) million for 2022[156]. - Innate Pharma's main source of income in the near- to medium-term is expected to come from payments under its license and collaboration agreements, as well as government grants and research tax credits[158]. - The company has incurred net losses in each year since its inception, except for 2016 and 2018, primarily due to costs associated with development programs and administrative expenses[156]. - Innate Pharma's ability to generate future revenue will depend on the regulatory approval of its product candidates and their market acceptance[159]. - The company anticipates significant increases in research and development expenses as it advances its product candidates through clinical studies and regulatory approvals[160]. Risk Management and Insurance - Product liability risks are inherent in the Company's business, with potential lawsuits that could divert resources and damage reputation[225]. - The Company has obtained product liability insurance coverage of €10 million per year, but this may not be sufficient to cover potential claims[227][229]. - Employee misconduct poses a risk to the Company, including violations of regulatory standards and insider trading, which could harm its business[230]. - The company has implemented a security policy to protect its data, but remains vulnerable to cyberattacks and other disruptions that could impact its operations[202]. Environmental and Safety Concerns - The Company is exposed to forest fire risks at its Research and Development facility and Headquarters in Luminy, France, which could lead to financial losses and operational disruptions[218]. - Fire prevention measures have been implemented, including pruning shrubs and maintaining fire-fighting equipment, but these do not guarantee complete safety from future fires[219]. - The Company handles hazardous materials and is subject to strict environmental and safety regulations, which could incur significant compliance costs[221][224].

EXHIBIT 99.1 Summary of Consolidated Financial Statements and Notes as of December 31, 2023 Consolidated Statements of Financial Position (in thousand euros) | | December 31, 2023 | December 31, 2022 | | --- | --- | --- | | Assets | | | | Cash and cash equivalents | 70,605 | 84,225 | | Short-term investments | 21,851 | 17,260 | | Trade receivables and others - current | 55,557 | 38,346 | | Total current assets | 148,012 | 139,831 | | Intangible assets | 416 | 1,556 | | Property and equipment | 6,322 | 8,542 ...

Company Participants Ashiq Mubarack - Citi Jingming Chen - Evercore ISI Daina Graybosch - Leerink Partners I'd now like to welcome Henry Wheeler to begin the conference. Henry, over to you. On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Mondher Mahjoubi I ...

The following interim condensed consolidated financial statements have been approved by the Executive Board of the Company on September 13, 2023, and have been subject to a limited review by our Statutory Auditors. They have been examined by the Supervisory Board of the Company on September 13, 2023. INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2023 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Board with a share capital of 4,026,535.85 euros composed of ...

Disclaimer on Forward-Looking Information and Risk Factors This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to i statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertairi cause the Company's actual results or financial condition to differ materially from those anticipated. Thes ...

Company Participants Ashiq Mubarack - Citigroup Daina Graybosch - SVB Securities Swayampakula Ramakanth - H.C. Wainwright & Co. Justine Telliez - Kepler Cheuvreux Jingming Chen - Evercore ISI Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release providing a business update for Q1 2023. We look forward to highlighting the progress made during the year todate as well as addressing future goals and milestones. The press release and today's presentation are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...